Although the potential of CXCR4 as a biomarker has been recognized much later than that of SSTRs it is fair to say that expression of CXCR4 is implicated in metastatic potential, therapeutic resistance, and hostile microenvironment in many solid tumors and hematologic malignancies which include B-cell lymphomas (14). This evidence concerns the gene CXCR4 and hematologic disorder.